Literature DB >> 22841809

Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii.

Nabil Karah1, Arnfinn Sundsfjord, Kevin Towner, Ørjan Samuelsen.   

Abstract

The global emergence of multidrug resistance (MDR) among Gram-negative bacteria has dramatically limited the therapeutic options. During the last two decades, Acinetobacter baumannii has become a pathogen of increased clinical importance due to its remarkable ability to cause outbreaks of infections and to acquire resistance to almost all currently used antibiotics, including the carbapenems. This review considers the literature on A. baumannii and data from multilocus sequence typing studies to explore the global population structure of A. baumannii and detect the occurrence of clonality, with the focus on the presence of specific resistance mechanisms such as the OXA-carbapenemases. The worldwide dissemination of MDR and carbapenem non-susceptible A. baumannii is associated with diverse genetic backgrounds, but predominated by a number of extensively distributed clones, such as CC92(B)/CC2(P) and CC109(B)/CC1(P), which have frequently been supplemented by acquired OXA-type carbapenemase genes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841809     DOI: 10.1016/j.drup.2012.06.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  97 in total

1.  Intercellular Transfer of Chromosomal Antimicrobial Resistance Genes between Acinetobacter baumannii Strains Mediated by Prophages.

Authors:  Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Investigation of the molecular epidemiology of Acinetobacter baumannii isolated from patients and environmental contamination.

Authors:  Chunmei Ying; Yongli Li; Yaping Wang; Bing Zheng; Chengde Yang
Journal:  J Antibiot (Tokyo)       Date:  2015-04-15       Impact factor: 2.649

3.  A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.

Authors:  Madeline R Galac; Erik Snesrud; Francois Lebreton; Jason Stam; Michael Julius; Ana C Ong; Rosslyn Maybank; Anthony R Jones; Yoon I Kwak; Kate Hinkle; Paige E Waterman; Emil P Lesho; Jason W Bennett; Patrick Mc Gann
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Bacterial peritonitis due to Acinetobacter baumannii sequence type 25 with plasmid-borne new delhi metallo-β-lactamase in Honduras.

Authors:  Paige E Waterman; Patrick McGann; Erik Snesrud; Robert J Clifford; Yoon I Kwak; Ivón P Munoz-Urbizo; Juana Tabora-Castellanos; Michael Milillo; Lan Preston; Ricardo Aviles; Deena E Sutter; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

5.  Emergence of Acinetobacter baumannii international clone II in Brazil: reflection of a global expansion.

Authors:  Natacha Martins; Libera Dalla-Costa; Aline Almeida Uehara; Lee Woodland Riley; Beatriz Meurer Moreira
Journal:  Infect Genet Evol       Date:  2013-10-10       Impact factor: 3.342

6.  Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35.

Authors:  Mariana Castanheira; Sarah E Costello; Leah N Woosley; Lalitagauri M Deshpande; Todd A Davies; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

7.  Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.

Authors:  Zubair A Qureshi; Lauren E Hittle; Jessica A O'Hara; Jesabel I Rivera; Alveena Syed; Ryan K Shields; Anthony W Pasculle; Robert K Ernst; Yohei Doi
Journal:  Clin Infect Dis       Date:  2015-01-28       Impact factor: 9.079

8.  Dissemination of a carbapenem-resistant Acinetobacter baumannii strain belonging to international clone II/sequence type 2 and harboring a novel AbaR4-like resistance island in Latvia.

Authors:  Mara Saule; Ørjan Samuelsen; Uga Dumpis; Arnfinn Sundsfjord; Aija Karlsone; Arta Balode; Edvins Miklasevics; Nabil Karah
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Pan-transcriptomic analysis identified common differentially expressed genes of Acinetobacter baumannii in response to polymyxin treatments.

Authors:  Mengyao Li; Su Mon Aye; Maizbha Uddin Ahmed; Mei-Ling Han; Chen Li; Jiangning Song; John D Boyce; David R Powell; Mohammad A K Azad; Tony Velkov; Yan Zhu; Jian Li
Journal:  Mol Omics       Date:  2020-05-29

10.  Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains.

Authors:  Jessica A O'Hara; Lauretta A Ambe; Leila G Casella; Bethany M Townsend; Mark R Pelletier; Robert K Ernst; Robert M Q Shanks; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.